Drug Profile
Research programme: HIV vaccines - GenVec
Alternative Names: HIV adenovector serotype Ad41 vaccine - GenVec/NIAID; Second-generation HIV vaccines - GenVec/SAIC-FrederickLatest Information Update: 29 Jun 2017
Price :
$50
*
At a glance
- Originator GenVec
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 16 Jun 2017 GenVec was acquired by Intrexon Corporation
- 28 Mar 2014 Discontinued - Preclinical for HIV-1 infections in USA (Parenteral)
- 04 Sep 2013 Research programme: HIV vaccines - GenVec is available for licensing as of 04 Sep 2013. http://www.genvec.com/